Karyopharm Therapeutics INC 8-K filings

Karyopharm Therapeutics reported Q2 2026 results, with total revenue at $33.4 million, and reaffirmed full-year guidance, while advancing its myelofibrosis program towards an sNDA submission.

Karyopharm Therapeutics reported topline data from its XPORT-EC-042 trial for endometrial cancer, which did not meet its primary endpoint, but also announced plans for a myelofibrosis sNDA submission.

Karyopharm Therapeutics Inc. announced a new retention program for key executives and the CFO to incentivize continued service through anticipated company catalysts.

Karyopharm Therapeutics stockholders approved a 3 million share increase to its equity incentive plan and the board authorized a new performance-based retention program for executives.

Karyopharm Therapeutics reported Q1 2026 financial results, highlighting $35.1M in total revenue and progress in key clinical trials for selinexor.

Karyopharm Therapeutics Inc. announced the closing of a private placement and additional open market sales, securing approximately $49.8 million in new capital.

Karyopharm Therapeutics announced a $30 million private placement and positive spleen volume reduction results from its Phase 3 SENTRY myelofibrosis trial, though a symptom endpoint was missed and DLBCL approval is being withdrawn.

Karyopharm Therapeutics stockholders approved an amendment to increase the company's authorized capital stock from 58.3 million to 111 million shares.

Karyopharm Therapeutics announced its Q4 and full-year 2025 financial results, reporting $146.1 million in total revenue and providing 2026 guidance, alongside updates on pivotal myelofibrosis and endometrial cancer trials.

Karyopharm Therapeutics announced preliminary unaudited 2025 revenue and cash figures, while highlighting key clinical trial milestones expected in 2026 for myelofibrosis and endometrial cancer.

Karyopharm Therapeutics announced increased Q3 2025 revenue and reduced operating loss, alongside key clinical trial advancements for its cancer therapies.

Karyopharm Therapeutics Inc. finalized a $131 million financing and recapitalization, issuing new convertible notes and warrants while restructuring existing debt.

Karyopharm Therapeutics announced comprehensive financing transactions providing $100 million in flexibility and capital, extending its cash runway into Q2 2026.

Karyopharm Therapeutics Inc. announced the resignation of Board Director Dr. Mansoor Raza Mirza, effective September 8, 2025, due to competing professional demands.

Karyopharm Therapeutics reported mixed Q2 2025 financial results with increased XPOVIO revenue but a significant net loss and reduced cash position, prompting exploration of financing and strategic alternatives.

Karyopharm Therapeutics is reducing its workforce by 20% and exploring strategic alternatives, including a potential sale, after confidential financing discussions did not result in a transaction, while continuing to advance its myelofibrosis and endometrial cancer programs.

Karyopharm Therapeutics Inc. announced the results of its 2025 Annual Meeting, where stockholders approved an increase of 450,000 shares for its equity incentive plan, re-elected two Class III directors, and supported annual advisory votes on executive compensation.

Karyopharm Therapeutics announced its Q1 2025 financial results, including a 5% increase in XPOVIO demand, and shared new data suggesting selinexor's potential in treating myelofibrosis.

Karyopharm Therapeutics will implement a 1-for-15 reverse stock split effective February 25, 2025, to meet Nasdaq's minimum bid price requirement.

Karyopharm reports $145 million in total revenue for 2024, updates Phase 3 XPORT-EC-042 trial, and anticipates top-line data from the SENTRY trial in the second half of 2025.

Karyopharm Therapeutics grants retention equity awards to its top executives to incentivize continued service.

Karyopharm Therapeutics Inc. stockholders approved an increase in authorized shares and authorized a reverse stock split at a special meeting held on January 30, 2025.

Karyopharm Therapeutics reported preliminary 2024 revenue figures and detailed its 2025 objectives, with a focus on the Phase 3 SENTRY trial for myelofibrosis.

Karyopharm Therapeutics has appointed Lori Macomber as its new Executive Vice President, Chief Financial Officer, and Treasurer, effective January 3, 2025.

Karyopharm Therapeutics is engaging with the FDA to discuss the evolving treatment landscape for endometrial cancer and its potential impact on the company's Phase 3 XPORT-EC-042 trial.

Karyopharm Therapeutics has appointed Kristin Abate as its new Chief Accounting Officer, effective November 20, 2024.

Karyopharm Therapeutics has amended its office lease, reducing its footprint by 46,278 square feet while extending the lease term for the remaining space by five years.

Karyopharm Therapeutics announced its third quarter 2024 financial results, highlighted by $38.8 million in total revenue and a narrowed full-year revenue guidance.

Karyopharm Therapeutics has changed a co-primary endpoint in its Phase 3 SENTRY trial for myelofibrosis treatment, replacing total symptom score improvement with absolute total symptom score after discussions with the FDA.

Karyopharm Therapeutics has received a notice from Nasdaq that its stock price has fallen below the minimum $1.00 threshold, potentially leading to delisting.